|
|
|
Amarillo Biosciences Appoints Bernard Cohen CFO |
 |
 |
 |
|
Tuesday, 29 September 2009 00:00 |
|
Amarillo, Texas, September 29, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has appointed Bernard Cohen as Chief Financial Officer (CFO). Mr. Cohen brings over thirty years of management experience to the position. Mr. Cohen replaces Dr. Gary Coy as CFO, who will assist the company with SEC filings as a consultant.
|
|
Last Updated on Wednesday, 07 October 2009 09:22 |
|
Read more... [Amarillo Biosciences Appoints Bernard Cohen CFO]
|
|
Amarillo Biosciences’ Phase 2 Australian Clinical Study Of Interferon As A Preventative Agent Against H1N1 Flu Virus And Other Cold And Flu Viruses Reaches Midway Point |
|
|
|
|
Tuesday, 08 September 2009 12:14 |
|
Amarillo, Texas, September 8, 2009 — Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that a Phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study in Perth, Australia achieved full target enrollment of 200 subjects and 98% of the subjects remain on study drug. Subjects in the study are receiving a lozenge containing interferon-alpha or a matching placebo once a day for 16 weeks. The average treatment time in the study to date is just over eight weeks. The first subject began treatment in May and the last subject will be completing blinded treatment in November, with final study results expected before the end of the year.
|
|
Last Updated on Tuesday, 08 September 2009 12:21 |
|
Read more... [Amarillo Biosciences’ Phase 2 Australian Clinical Study Of Interferon As A Preventative Agent Against H1N1 Flu Virus And Other Cold And Flu Viruses Reaches Midway Point]
|
|
|
Dr. Manfred Beilharz, Co-Investigator in Australian Influenza Phase 2 Clinical Trial, Interviewed on 6PR Nightline Program Regarding Interferon and Influenza |
|
|
|
|
Thursday, 20 August 2009 12:26 |
|
Amarillo, Texas, August 17, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Manfred Beilharz, Chairman of the Department of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences at the University of Western Australia was recently interviewed by Graham Mabury on 6PR Nightline, a radio program in Australia. Dr. Beilharz is a co-investigator of the ongoing Phase 2, 200-subject clinical trial that is testing the efficacy of ABI’s oral interferon alpha in preventing influenza and winter colds.
|
|
Last Updated on Thursday, 20 August 2009 12:46 |
|
Read more... [Dr. Manfred Beilharz, Co-Investigator in Australian Influenza Phase 2 Clinical Trial, Interviewed on 6PR Nightline Program Regarding Interferon and Influenza]
|
|
Amarillo Biosciences Reaches Enrollment Goal in Australian Influenza Phase 2 Clinical Trial |
|
|
|
|
Wednesday, 05 August 2009 07:55 |
|
Amarillo, Texas, July 10, 2009 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has reached full enrollment in a Phase 2 clinical study of the company’s oral interferon product at the University of Western Australia located in Perth. A total of 200 healthy volunteers meeting all eligibility criteria have been enrolled to 16 weeks of treatment with oral interferon or matching placebo.
|
|
Last Updated on Wednesday, 05 August 2009 08:34 |
|
Read more... [Amarillo Biosciences Reaches Enrollment Goal in Australian Influenza Phase 2 Clinical Trial]
|
|
|
|
|
<< Start < Prev 1 2 3 4 5 Next > End >>
|
|
Page 3 of 5 |